Pembrolizumab-Belzutifan Combination Improves Renal Cancer Survival in NEJM Trial
Sourced from 4 publications
- •A study in the New England Journal of Medicine reported that pembrolizumab-belzutifan significantly improves disease-free survival in clear-cell renal cell carcinoma patients.
- •Celltrion's bevacizumab biosimilar Vegzelma gained preferred formulary status with major U.S. pharmacy benefit managers, reducing insurance access barriers.
- •Novartis will pay $1.5 billion to acquire Myricx Bio for its novel antibody-drug conjugate payload technology.
- •ADC-focused acquisitions continue to dominate oncology dealmaking, with Novartis joining a crowded field of buyers.
Sources
Pembrolizumab-belzutifan tied to improved disease-free survival in renal cell ca...
Medicalxpress
Celltrion’s Vegzelma Clears Key U.S. Insurance Hurdle With Major PBM Listings
Koreaittimes
Celltrion Vegzelma Gains Key U.S. PBM Listings
Businesskorea
Novartis to pay $1.5B for Myricx Bio and its novel ADC payloads
bioworld
Curated from 4 sources. Every summary is reviewed for accuracy, but may still contain errors. We always link to original sources for verification.
Related Stories
About Meridian
Meridian is a free daily newsletter delivering signal-scored news stories with forward-looking analysis every morning. Stories are scored across six criteria (global leverage, capital impact, temporal durability, career relevance, decision utility, and narrative clarity) then assigned to Big Signal, Core, or Quick tiers.
Get Meridian in your inbox
The stories that matter, every morning at 06:00.